Olema Pharmaceuticals (OLMA) Income towards Parent Company (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Income towards Parent Company data on file, last reported at -$145.1 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 358.18% year-over-year to -$145.1 million in Q1 2026; TTM through Mar 2026 was -$279.5 million, a 31.89% decrease from a year earlier, with the FY2025 full-year figure at -$398.1 million, down 190.41% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$145.1 million, down from -$46.1 million in the prior quarter.
• Over the last five years, Income towards Parent Company for OLMA reached as high as -$25.8 million in Q3 2022 and fell as low as -$145.1 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$50.8 million across 5 years, with a median of -$42.5 million in 2025.
• Across the five-year window, Income towards Parent Company jumped 78.22% in 2022 and sank 358.18% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$26.6 million in 2022, then decreased by 2.1% to -$27.1 million in 2023, then declined by 24.52% to -$33.8 million in 2024, then plunged by 36.39% to -$46.1 million in 2025, then plunged by 214.93% to -$145.1 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$145.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.5 million in Q3 2025.